Maxine Seales Kasangana, MD
Infectious Disease · Duluth, MNNPI 1417260704
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $127 and has fallen 58.8% since, to $52 in 2024.
Across 19 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$51
- Actelion Pharmaceuticals US, Inc.$51
- Insmed, Inc.$51
- Jazz Pharmaceuticals Inc.$37
- Harmony Biosciences LLC$30
- Takeda Pharmaceuticals U.S.A., Inc.$29
- plus $106 from 7 others
What the payments were for
- Food & beverage$33895%
- Education$165%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 3 | $51 |
| Actelion Pharmaceuticals US, Inc. | 2 | $51 |
| Insmed, Inc. | 2 | $51 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Harmony Biosciences LLC | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Viiv Healthcare Company | 1 | $13 |
| Nevro Corp. | 1 | $13 |
| Sandoz | 1 | $13 |
How this compares
$355 in reported general payments places this provider in the 80th percentile of 157 infectious disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 74 | $294,308 |
| Daptomycin | 15 | $28,713 |
| Vancomycin Hcl | 79 | $13,239 |
| Cefepime Hcl | 37 | $10,622 |
| Methenamine Hippurate | 128 | $6,662 |
| ErtapenemErtapenem Sodium | 14 | $5,708 |
| Itraconazole | 26 | $1,512 |
| CeftriaxoneCeftriaxone Sodium | 15 | $1,213 |
| Estradiol | 15 | $1,196 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 11 | $880 |
| NitrofurantoinNitrofurantoin Macrocrystal | 30 | $803 |
| Fluconazole | 19 | $708 |
| Cefazolin Sodium | 20 | $641 |
| Cefadroxil | 35 | $421 |
| Doxycycline Hyclate | 24 | $220 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Duluth
- Jordan TichenorDuluth$682
- Rajesh PrabhuDuluth$114
- Andrew ThompsonDuluth$65
- Tze-Chiang MengLino Lakes$132K
- Frank RhameMinneapolis$132K
- Zelalem TemesgenRochester$46K
- Nathan CumminsRochester$44K
- Andrew BadleyRochester$22K
- Raymund RazonableRochester$20K
- Marisa AzadRochester$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.